

Future Collaboration Opportunities

Breakouts: Methods Research | Data Standards | Open-Source Development | Clinical Applications

OHDSI Community Call Nov. 2, 2021 • 11 am ET

n ohdsi





Nov. 9: Future Collaboration Opportunity Breakouts

Open-Source



Jenna Reps



Martijn Schuemie




Clair Blacketer



Maxim Moinat



Adam Black



Anthony Sena



Talita Duarte-Salles



Clinical

Asieh Golozar





Remaining 2021 OHDSI Community Calls

Date	Topic
Nov. 2	Collaboration Opportunities: Methods Res., Data Standards, Open-Source, Clinical App.
Nov. 9	Demos: Tools for Adoption of OHDSI Data Standards
Nov. 16	Open Network Studies
Nov. 23	History of OHDSI
Nov. 30	Collaborator Showcase Presentations
Dec. 7	How Did We Do This Year? Final OKR Review
Dec. 14	Holiday-Themed Final Meeting Of 2021







Remaining 2021 OHDSI Community Calls

Date	Topic	
Nov. 2	Collaboration Opportunities: Methods Res., Data Standards, Open-Source, Clinical App.	
Nov. 9	Demos: Tools for Adoption of OHDSI Data Standards	
Nov. 16	Open Network Studies	
Nov. 23	History of OHDSI	
Nov. 30	Collaborator Showcase Presentations	
Dec. 7	How Did We Do This Year? Final OKR Review	
Dec. 14	Holiday-Themed Final Meeting Of 2021	







Nov. 9: Tools For Adoption Of OHDSI Data Standards



Introduction To CDM 5.4





Michael Kallfelz

OHDSI Vocabularies



ETL Inspection Report



Three Stages of The Journey

Where Have We Been?
Where Are We Now?
Where Are We Going?







Upcoming Workgroup Calls



Date	Time (ET)	Meeting
Tuesday	1 pm	Common Data Model
Tuesday	2 pm	Health Equity
Tuesday	3 pm	OMOP CDM Oncology – Outreach/Research Subgroup
Wednesday	2 am (4 pm KST)	Patient-Level Prediction/Population-Level Estimation (Eastern Hemi)
Wednesday	10 am	OMOP CDM Oncology – Development Subgroup
Wednesday	7 pm	Medical Imaging
Thursday	10 am	Medical Devices
Thursday	12 pm	Patient-Level Prediction/Population-Level Estimation (Western Hemi)
Thursday	1 pm	OMOP CDM Oncology – CDM/Vocabulary Subgroup
Friday	9 am	Education
Friday	9 am	Vaccine Vocabulary
Monday	8 am	Early-Stage Researchers (Europe/Western Hemisphere)
Monday	10 am	GIS-Geographic Information System
Tuesday	9 am	OMOP CDM Oncology – Genomic Subgroup

www.ohdsi.org/upcoming-working-group-calls



in ohdsi



Get Access To Different Teams/WGs/Chapters




ATLAS		
Clinical Trials		
Common Data Model	Phenotype Development and Evaluation	
Data Quality Dashboard Development	Population-Level Effect Estimation / Patient-Level Prediction	
Early-stage Researchers	☐ Psychiatry	
	Registry (formerly UK Biobank)	
Education Work Group	Surgery and Perioperative Medicine	
Electronic Health Record (EHR) ETL	☐ Vaccine Safety	
Geographic Information System (GIS)	☐ Vaccine Vocabulary	
HADES Health Analytics Data-to-Evidence Suite	☐ Women of OHDSI	
Health Equity		
Latin America	6. Select the chapter(s) you want to join	
Laun America	Africa	
Medical Devices	Australia	
Natural Language Processing	China	
OHDSI APAC	Europe	
OTIDSI AFAC	Japan	
OHDSI APAC Steering Committee	☐ Korea	
OHDSI Steering Committee	Singapore	
Oncology	☐ Taiwan	
Patient-Generated Health Data		
Pharmacovigiliance Evidence Investigation	7. Select the studies you want to join	
Pharmacovigiliance Evidence Investigation	HERA-Health Equity Research Assessment	





Get Access To Different Teams/WGs/Chapters



ATLAS		
Clinical Trials		
Common Data Model		
Data Quality Dashboard Development	Phenotype Development and Evaluation	
Early-stage Researchers	Population-Level Effect Estimation / Patient-Level Prediction	
	☐ Psychiatry	
Education Work Group	Registry (formerly UK Biobank)	
Electronic Health Record (EHR) ETL	Surgery and Perioperative Medicine	
Geographic Information System (GIS)	☐ Vaccine Safety	
deographic information system (dis)	☐ Vaccine Vocabulary	
HADES Health Analytics Data-to-Evidence Suite	☐ Women of OHDSI	
Health Equity		
Latin America	6. Select the chapter(s) you want to join	
Medical Devices	Africa	
Medical Devices	Australia	
Natural Language Processing	China	
OHDSI APAC	Europe	
OUDGLADAG Chassing Constitutes	Japan	
OHDSI APAC Steering Committee	☐ Korea	
OHDSI Steering Committee	Singapore	
Oncology	Talwan	
Patient-Generated Health Data		
Pharmacovigiliance Evidence Investigation	7. Select the studies you want to join	





2021 APAC Symposium • Nov. 18

Nov. 18 (APAC Time Zone)	Time (Korea time)	Contents	Speaker(s)
	9:00 – 9:25 am	OHDSI State of the Community	George Hripcsak/Patrick Ryan
	9:25 – 9:50 am	OHDSI APAC State of the Community	Mui Van Zandt
	9:50 – 10:00 am	Energy Break	
	10:00 – 10:25 am	EHDEN	Peter Rijnbeek
Morning	10:25 – 10:50 am	FHIR and OHDSI Collaboration	Christian Reich
	10:50 – 11:00 am	Energy Break	
	11:00 - 12:30 pm	APAC Chapter Visions for 2022	Chapter Leads
Lunch Break	12:30 – 13:00 pm		
Afternoon (in	13:00 – 14:00 pm	Workgroup Sessions (Medical Image, FHIR, CDM Tables)	
GatherTown)	14:00 – 15:00 pm	Collaboration Showcase	
	15:00 – 16:00 pm	APAC Study Sessions	

www.ohdsi.org/apac



in ohdsi



New OMOP Modeling and OHDSI Tools Course





Latest Edition Of The Journey Newsletter

Community Updates

Where Have We Been

 Recordings, materials and other resources from the first workshop between HL7 and OHDSI are now available here. Five new subgroups have been formed to advance the use cases/projects: <u>Data Model Harmonization</u>, <u>Digital Quality Measurement</u>, <u>Oncology</u>, <u>Registries and Applications</u>, and <u>Terminologies</u>. The FHIR and OMOP workgroup has returned, so if you would like to join this collaborative effort, <u>please sign up here</u>.

• Patrick Ryan recently led a Halloween-themed interactive demonstration of how you can use the OHDSI tools to quickly generate insights from your OMOP CDM. This demo is now available for anybody to watch.

Where Are We Now

- Nov. 1 marks the official start date of the LEGEND Initiative study around type 2 diabetes. This announcement follows the release of the research protocol on MedRxiv and a presentation on the Initiative by the LEGEND team.
 More on the LEGEND Initiative is available later in this newsletter.
- As announced recently, CDM v5.4 has been released and is available to the OHDSI Community. CDM workgroup leader Clair Blacketer will provide a live demo on the new version during the Nov. 9 community call.
- We are now in our second month of the #OHDSISocialShowcase, which highlights all of the global research shared during the 2021 Global Symposium. Each weekday, one presentation will be highlighted on both our Twitter and LinkedIn feeds. Please share with your networks to spread the word about our global efforts!

Where Are We Going

- The 2021 Asia-Pacific (APAC) Symposium will be held virtually Nov. 18 (Korea time), and will feature both a series of talks and an afternoon of collaborative activities, including workgroup meetings, a collaborator showcase and study sessions. You can register for the APAC Symposium now, and more information on the event is available later in this newsletter.
- The upcoming month of community calls will feature breakouts for collaboration opportunities, presentations on open network studies within the community, a discussion on the history of OHDSI, and plenty more. Check out the full November schedule below; our meetings are held Tuesdays at 11 am ET, and everybody is invited. If you missed any, all presentations are recorded and posted to our community calls homepage.

The Journey Newsletter (November 2021)

The LEGEND (Large-scale Evidence Generation and Evaluation across a Network of Databases) Initiative has already resulted in several published studies in high-impact journals, and the team has a new focus in store. You can learn more about this work, look ahead to the upcoming Asia-Pacific Symposium, and get more community updates in this edition of The Journey. #JoinTheJourney

Monthly Update Podcast



The LEGEND Initiative — What Is It, How Did It Impact Hypertension, And What Comes Next?



The LEGEND (Large-scale Evidence Generation and Evaluation across a Network of Databases) Initiative applies high-level analytics to perform observational research on hundreds of millions of patient records within OHDSI's international database network.

LEGEND principles have been applied to studying the effects of treatments for depression, hypertension, and COVID-19, and are being applied to Type 2 diabetes. The clinical impact of LEGEND has already been observed, with important evidence that promotes better health decisions published in Lancet, JAMA Internal Medicine, and Hypertension.

During the Oct. 19 OHDSI Community Call, members of the LEGEND team provided a comprehensive presentation around this initiative, its work around hypertension, and plans around Type 2 diabetes.

Watch The LEGEND Initiative Presentation


Find Study Protocol, Study Package, Presentation Slides



n ohdsi




Latest Edition Of The Journey Newsletter











Contact: Elisa.Henke@ukdd.de

MONDAY

Development of an ETL Process for Bulk and Incremental Load of German Patient **Data into OMOP CDM Using FHIR**

Authors: Elisa Henke, Yuan Peng, Ines Reinecke, Michele Zoch, Martin Sedlmayr

#JoinTheJourney



ohdsi







Evaluating the performance of Austin's standardized difference heuristic in observational cohort studies with varying sample size

Mitch Conover¹, Azza Shoaibi¹, Joshua Ide¹, Martijn Schuemie¹

OHDSI PLE/PLP Working Group September 3, 2021

¹All authors are employees of Janssen Research & Development


TUESDAY

Evaluating the performance of Austin's standardized difference heuristic in observational cohort studies with varying sample size Authors: Mitchell Conover (presenter), Azza Shoaibi, Joshua Ide, Martijn Schuemie









WEDNESDAY

Assessing the Technical and Operational Feasibility of a Next-generation Data Capture and Processing Approach An Extension of OMOP-based Data Translation Developed by the Center for International Blood and Marrow Transplant Research (CIBMTR)

Authors: Ben Smith, Trent Peterson, Kristina Bloomquist





Mapping UK Biobank to the OMOP CDM: challenges and solutions using the Delphyne ETL framework

ifia Bazakou* ⁽¹⁾, Maxim Moinat⁽¹⁾, Alessia Peviani⁽¹⁾, Anne van Winzum⁽¹⁾, Stefan Payralbe⁽¹⁾, Vaclav Papez⁽²⁾, Spiros Denaxas⁽²⁾

The Hyve, Utrecht, The Netherlands * Contact: sofia@thehyve.nl / +31 (0)30 7009713

University College London, London, United Kingdom



Background

UK Biobank¹ (UKB) is a large-scale registry containing medical and genetic data from 500,000 consented participants from the UK¹s general population, aged between 40 and 69 years (Figure 1). UKB is an extraordinary resource for human health research, accessible to approved research initiatives worldwide.




Figure 1. UKB data structure and timeline. The data include baseline assessments (light green), such as surveys, samples, and imaging, electronic health records (EHR) from different sources (dark green), and information on COVID-19 testing (red). Picture adapted from Spiros Denaxas, Professor of Biomedical Informatics, Institute of Health Informatics, University College London.

As part of the European Health Data Evidence Network² (EHDEN), The Hyve was contracted by University College London (UCL) to map the UKB data to the OMOP CDM v5.3. The main goal of the collaboration was to make the dataset available for research related to the COVID-19 pandemic. The Hyve implemented the data conversion pipetine, white UCL provided the source data expertise.

The UKB data conversion effort came with several challenges:

- · ETL development without direct access to the data.
- · Mapping of free-text and non-standard ontologies.
- Large heterogeneity of source terms amongst data providers.
- Conversion of a large wide format table to long format.
- Working with an evolving data source.

Methods

The Hyve overcame the lack of direct access to the UKB data by adopting a collaborative Agile-based development approach with UCL (Figure 2). This process made it possible to develop the ETL code relying entirely on synthetic data.



Figure 2. Collaborative Agile development approach using existing OHDSI tools and Delphyne. Step 1: UCL provided a White Rabbid scan report of the URB data, which The Hyve used to generate synthetic data for ETL development. Step 2: The Hyve performed syntactic and semantic mapping with Rabbit in a fixt and Usagi, respectively, and developed the ETL with Delphyne. Step 3: U.C. ran the ETL locally (deployed with Decker) on a URB data subset, and executed quality thecks with Achilies and the Data Quality Banhacon. The Hyve registed the ETL based on feedback Refuer a new

Our UKB mapping workflow made use of existing tools from the OHDSI suite and Delphyne³-4, a specialized ETL framework for mapping data to the OMOP CDM, developed internally by The Hyve. Delphyne was particularly helpful in tackling data heterogeneity between UKB healthcare providers, and the mapping of the wide format baseline table (500,000x9,000), which both required specific handling logic. Our development approach relied heavily on feedback, which Delphyne helped to provide through detailed logging and summary reports. It also made trivial to extend the CDM model with custom provenance fields, enabling more informative data quality assessments. Finally, Delphyne automated several tasks, such as CDM table creation, vocabulary loading, and mapping of non-standard to standard ontologies, saving time whenever a UKB data or vocabulary update was available. Overall, Delphyne allowed us to build a highly specialized ETL, for maximum mapping coverage and quality.

Conclusion

UKB is an incredible resource for healthcare research. Given its size and complexity, mapping the data to the OMOP CDM model came with several challenges. A powerful and flexible ETL framework such as Delphyne was invaluable in carrying out the conversion effort. Together with existing open-source tools from the OHDSI suite, Delphyne allowed us to perform the conversion without direct access to the UKB data, and to deliver a high-coverage mapping (Figure 3). The mapping of UKB data to the OMOP CDM will in turn enable future research, including studies on COVID-19, to build upon our efforts.



Figure 3. Percentage of UKB source codes mapped to a standard OMOP concept per domain, by record frequency. We ochieved a near full mapping coverage for the Visit, Device and Condition domains (>99%), and the lowest mapping coverage for the Drug domain (86%). Note that for the baseline data mapping, we converted a subset of the original variables.

References

[1] https://www.ukbiobank.ac.uk/

[2] https://ehden.eu/

[3] https://www.thehyve.nl/cases/mapping-uk-biobank-to-omop-using-delphyne

[4] https://delphyne.readthedocs.io/en/latest/

±UCL






THURSDAY

Mapping UK Biobank to the OMOP CDM: challenges and solutions using the delphyne ETL framework

Authors: Sofia Bazakou, Maxim Moinat, Alessia Peviani, Anne van Winzum, Stefan Payralbe, Vaclav Papez, Spiros Denaxas





FRIDAY

Perseus Design and run your own ETL to CDM

Authors: Anton Ivanov, Samus Sergey, Alexander Efimov, Maxim Draschinsky





Three Stages of The Journey

Where Have We Been? Where Are We Now? Where Are We Going?







Where Are We Going?

Any other announcements of upcoming work, events, deadlines, etc?








Three Stages of The Journey

Where Have We Been? Where Are We Now? Where Are We Going?









Congratulations to Antoine Lamer, Osama Abou-Arab, Alexandre Bourgeois, Adrien Parrot, Benjamin Popoff, Jean-Baptiste Beuscart, Benoît Tavernier, and **Mouhamed Djahoum Moussa for the** publication of "Transforming Anesthesia **Data Into the Observational Medical Outcomes Partnership Common Data Model: Development and Usability Study"** in the Journal of Medical Internet Research.









Congratulations to William Wood, Peter Marks, Robert Plovnick, Kathleen Hewitt, Donna Neuberg, Sam Walters, Brendan **Dolan, Emily Tucker, Charles Abrams, Alexis** Thompson, Kenneth Anderson, Paul Kluetz, Ann Farrell, Donna Rivera, Matthew Gertzog, and Gregory Pappas for the publication of "ASH Research Collaborative: A Real-World Data Infrastructure to Support **Real-World Evidence Development and Learning Healthcare Systems in** Hematology" in Blood Advances.



American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 Phone: 202-776-0544 | Fax 202-776-054

ASH Research Collaborative: A Real-World Data Infrastructure to Support Real-World Evidence Development and Learning Healthcare Systems in Hematology

Tracking no: ADV-2021-005902R1

William Wood (University of North Carolina at Chapel Hill, United States) Peter Marks (Food and Drug Administration, United States) Robert Plovnick (American Society of Hematology, United States) Kathleen Hewitt (ASH Research Collaborative, United States) Donna Neuberg (Dana-Farber Cancer Institute, United States) Sam Walters (Breakthrough Healthcare, United States) Brendan Dolan (The University of Wisconsin School of Medicine and Public Health, United States) Emily Tucker (ASH Research Collaborative, United States) Charles Abrams (University of Pennsylvania School of Medicine, United States) Alexis Thompson (Ann & Robert H. Lurie Children's Hospital of Chicago/Northwestern Univ, United States) Kenneth Anderson (Dana-Farber Cancer Institute, United States) Paul Kluetz (Oncology Center of Excellence, Food and Drug Administration, United States) Ann Farrell (US FDA, United States) Donna Rivera (Oncology Center of Excellence, Food and Drug Administration, United States) Gregory Pappas (Food and Drug Administration, United States)

Abstract:

The ASH Research Collaborative is a nonprofit organization established through the American Society of Hematology's commitment to patients with hematologic conditions and the science that informs clinical care and future therapies. The ASH Research Collaborative houses two major initiatives: 1) the Data Hub and 2) the Clinical Trials Network (CTN). The Data Hub is a program for hematologic diseases in which networks of clinical care delivery sites are developed in specific disease areas, with individual patient data contributed through electronic health record (EHR) integration, direct data entry through electronic data capture, and external data sources. Disease-specific data models are constructed so that data can be assembled into analytic datasets and used to enhance clinical care through dashboards and other mechanisms. Initial models have been built in multiple myeloma and sickle cell disease using the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) and Fast Healthcare Interoperability Resources (FHIR) standards. The Data Hub also provides a framework for the development of disease-specific Learning Communities and the testing of healthcare delivery strategies. The ASH Research Collaborative CTN is a clinical trials accelerator that creates efficiencies in the execution of multicenter clinical trials and has been initially developed for sickle cell disease. Both components are operational, with the Data Hub actively aggregating source data and the CTN reviewing study candidates. This manuscript describes processes involved in developing core features of the ASH Research Collaborative to inform the stakeholder community in preparation for expansion to additional disease











INFORMATICS PROFESSIONALS, LEADING THE WAY.

Patrick Ryan
Inductee

ACMI Fellows Class of 2021 Induction Ceremony (ACMI Fellows Only)

11:30 am PT • Sapphire M

d COLUMBIA

COLUMBIA UNIVERSITY
DEPARTMENT OF
BLOMEDICAL INFORMATICS

Congratulations to those new #ACMI Fellows in person with us in San Diego! #AMIA2021









